Serious adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with symptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Serious adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).
1 finding from 1 review
Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse eventsh · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine showed no clear difference in serious adverse eventsh compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults and children with uncomplicated malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events compared with other antimalarials (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
Tacrolimus showed no clear difference in serious adverse events compared with beclometasone (low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children under 18 years of age with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with asthma
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review